Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
McKinsey
Dow
Mallinckrodt
Moodys

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR INSULIN DETEMIR RECOMBINANT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Insulin Detemir Recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00095082 ↗ Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes Completed Novo Nordisk A/S Phase 3 2004-09-01 This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.
NCT00097084 ↗ Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2004-09-01 This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type 2 diabetes.
NCT00104182 ↗ Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2005-02-01 This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment with oral antidiabetic drugs in patients with Type 2 diabetes.
NCT00106366 ↗ Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2005-03-01 This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.
NCT00117780 ↗ Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes Completed Novo Nordisk A/S Phase 4 2005-06-01 This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insulin detemir twice daily injection administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight and side effects).
NCT00184600 ↗ Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2004-11-01 This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir, insulin aspart and biphasic insulin aspart 30, when added to current OAD (oral anti-diabetic drug) treatment in subjects with type 2 diabetes and to verify the safety of use (number and severity of episodes of hypoglycaemia, body weight and side effects).
NCT00184639 ↗ Comparison of Insulin Detemir and Insulin Semilente┬«MC in Type 1 Diabetes Completed Novo Nordisk A/S Phase 3 2004-08-16 This trial is conducted in Europe. A 32-week efficacy and safety comparison of insulin detemir and insulin semilente MC in children between 6 and 21 years with type 1 diabetes.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Detemir Recombinant

Condition Name

Condition Name for Insulin Detemir Recombinant
Intervention Trials
Diabetes 122
Diabetes Mellitus, Type 2 87
Diabetes Mellitus, Type 1 58
Type 2 Diabetes Mellitus 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Detemir Recombinant
Intervention Trials
Diabetes Mellitus 163
Diabetes Mellitus, Type 2 109
Diabetes Mellitus, Type 1 71
Overweight 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Detemir Recombinant

Trials by Country

Trials by Country for Insulin Detemir Recombinant
Location Trials
United States 561
Canada 50
United Kingdom 38
France 31
Germany 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Detemir Recombinant
Location Trials
Texas 32
California 30
Georgia 24
Florida 23
New York 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Detemir Recombinant

Clinical Trial Phase

Clinical Trial Phase for Insulin Detemir Recombinant
Clinical Trial Phase Trials
Phase 4 51
Phase 3 50
Phase 2 6
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Detemir Recombinant
Clinical Trial Phase Trials
Completed 164
Terminated 12
Unknown status 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Detemir Recombinant

Sponsor Name

Sponsor Name for Insulin Detemir Recombinant
Sponsor Trials
Novo Nordisk A/S 141
Sanofi 5
Eli Lilly and Company 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Detemir Recombinant
Sponsor Trials
Industry 167
Other 91
U.S. Fed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
McKinsey
Moodys
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.